Proteo Inc. (PTEO.OB) /Proteo Biotech AG (PTEO.OB): FDA Grants Orphan Drug Designation to Elafin for Prevention of Inflammatory Complications of Transthoracic Esophagectomy
3/21/2013 11:27:19 AM
More...
|
Proteo Inc. (PTEO.OB)/ Proteo Biotech AG (PTEO.OB): Proteo's Elafin Will Be Tested at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)
6/18/2010 6:22:05 AM
More...
|
Proteo Inc. (PTEO.OB)/Proteo Biotech AG (PTEO.OB): Successful Completion of Patient Recruitment for the Phase II Clinical Trial on Elafin in Patients with Esophagus Cancer
4/23/2010 10:03:28 AM
More...
|
Proteo Inc. (PTEO.OB)/Proteo Biotech AG (PTEO.OB): European Medicines Agency European Medicines Evaluation Agency Recommends Orphan Drug Status for Elafin in the Treatment of Esophagus Carcinoma
11/16/2009 10:16:17 AM
More...
|
Proteo Inc. (PTEO.OB)/Proteo Biotech AG (PTEO.OB) - Minapharm/Rhein Minapharm Biogenetics SAE: Approval for a Phase II Clinical Trial with Elafin in Kidney Transplantation
12/10/2008 10:04:58 AM
More...
|
Proteo Inc. (PTEO.OB)/Proteo Biotech AG (PTEO.OB): Start of the Phase II Clinical Trial With Elafin
11/17/2008 11:36:42 AM
More...
|
Proteo Inc. (PTEO.OB)/Proteo Biotech AG (PTEO.OB) - Minapharm/Rhein Minapharm Biogenetics SAE: Proteo Biotech AG (PTEO.OB), Germany and Minapharm, Egypt Enter into Development and License Agreement for Elafin
8/9/2007 1:28:30 PM
More...
|
Proteo Inc. (PTEO.OB)/Proteo Biotech AG (PTEO.OB): European Commission grants Orphan Drug Status to Elafin for the treatment of PAH
3/29/2007 12:30:26 PM
More...
|
Proteo Biotech AG (PTEO.OB) And Proteo Inc. (PTEO.OB) Anti-Inflammatory Agent "Elafin" Has Been Successfully Tested In A Phase I Clinical Trial
12/13/2005 11:50:24 AM
More...
|
Proteo Inc. (PTEO.OB) / Proteo Biotech AG (PTEO.OB) Commissions The Manufacture Of Elafin To GMP-Standards In Belgium; Elafin For Clinical Testing
10/19/2005 5:13:14 PM
More...
|
|